医学
铁蔗糖
贫血
随机对照试验
临床终点
生活质量(医疗保健)
静脉注射铁
内科学
血红蛋白
胃肠病学
打开标签
缺铁性贫血
多中心研究
外科
缺铁
护理部
作者
Sanghoon Lee,Ki‐Jin Ryu,Eun Sil Lee,Keun Ho Lee,Jeong Jae Lee,Tak Kim
出处
期刊:Journal of obstetrics and gynaecology research
[Wiley]
日期:2019-04-01
卷期号:45 (4): 858-864
被引量:39
摘要
AIM: To compare ferric carboxymaltose (FCM) with iron sucrose (IS) for the effective and timely treatment of preoperative iron deficiency anemia (IDA) in women with menorrhagia. METHODS: This open-label, multicenter, two-arm study randomized patients to receive either a single dose of FCM or multiple doses of IS. The primary endpoint was the proportion of patients who achieved hemoglobin (Hb) levels ≥10 g/dL within 2 weeks after the first administration. Secondary endpoints included mean Hb levels, time to reach Hb ≥10 g/dL and quality of life (QoL). RESULTS: In total, 101 patients (FCM n = 52; IS n = 49) were randomized to the study treatments. FCM was as effective as IS in achieving Hb ≥10 g/dL within 2 weeks after the first administration (78.8% vs 72.3%). The time to reach Hb ≥10 g/dL was significantly shorter in the FCM group than in the IS group (7.7 days vs 10.5 days). Mean Hb levels were higher in the FCM-treated patients than in the IS-treated patients with borderline significance. QoL scores did not differ between the two groups. CONCLUSION: Ferric carboxymaltose is as effective as IS in correcting preoperative IDA among patients with menorrhagia. The added benefits of FCM over IS included significant rapid correction of IDA, replenishment of iron stores and reduced hospital visits.
科研通智能强力驱动
Strongly Powered by AbleSci AI